Jennison Associates LLC Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Jennison Associates LLC cut its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 410,057 shares of the company’s stock after selling 110,333 shares during the quarter. Jennison Associates LLC’s holdings in Krystal Biotech were worth $74,643,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of KRYS. State Board of Administration of Florida Retirement System raised its stake in Krystal Biotech by 18.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock worth $1,300,000 after buying an additional 1,140 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Krystal Biotech by 80.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock worth $557,000 after acquiring an additional 1,397 shares in the last quarter. Capital World Investors purchased a new position in shares of Krystal Biotech in the 1st quarter valued at approximately $17,285,000. Affinity Asset Advisors LLC boosted its position in shares of Krystal Biotech by 7.0% during the first quarter. Affinity Asset Advisors LLC now owns 26,746 shares of the company’s stock valued at $4,759,000 after purchasing an additional 1,746 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in Krystal Biotech by 27.5% in the first quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after purchasing an additional 282 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KRYS shares. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Chardan Capital lifted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average price target of $202.29.

Krystal Biotech Stock Up 0.1 %

Shares of KRYS opened at $178.10 on Thursday. Krystal Biotech, Inc. has a twelve month low of $99.00 and a twelve month high of $219.34. The company has a market capitalization of $5.12 billion, a P/E ratio of 100.62 and a beta of 0.82. The firm has a 50 day moving average of $180.45 and a 200 day moving average of $182.02.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter last year, the company earned ($0.67) EPS. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).